NASDAQ:AKCA - Akcea Therapeutics Stock Price, Forecast & News

Akcea Therapeutics' stock was trading at $13.44 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, AKCA shares have decreased by 1.0% and is now trading at $13.31. View which stocks have been mosted impacted by Coronavirus.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Akcea Therapeutics in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Akcea Therapeutics.

Akcea Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, May 13th 2020. View our earnings forecast for Akcea Therapeutics.

Akcea Therapeutics Inc (NASDAQ:AKCA) announced its earnings results on Tuesday, February, 25th. The company reported $0.86 earnings per share for the quarter, missing analysts' consensus estimates of $2.10 by $1.24. The firm earned $277.48 million during the quarter, compared to analyst estimates of $225.94 million. Akcea Therapeutics had a return on equity of 10.03% and a net margin of 8.35%. The business's revenue was up 2620.4% on a year-over-year basis. During the same quarter last year, the firm earned ($0.79) EPS. View Akcea Therapeutics' earnings history.

4 brokers have issued 12-month target prices for Akcea Therapeutics' shares. Their forecasts range from $24.00 to $41.00. On average, they anticipate Akcea Therapeutics' share price to reach $34.67 in the next twelve months. This suggests a possible upside of 160.5% from the stock's current price. View analysts' price targets for Akcea Therapeutics.

News stories about AKCA stock have trended somewhat negative recently, according to InfoTrie Sentiment Analysis. InfoTrie ranks the sentiment of press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Akcea Therapeutics earned a media sentiment score of -1.0 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View the latest news aboutAkcea Therapeutics.

Akcea Therapeutics saw a decrease in short interest during the month of March. As of March 13th, there was short interest totaling 3,366,000 shares, a decrease of 7.0% from the February 27th total of 3,620,000 shares. Based on an average daily volume of 254,300 shares, the days-to-cover ratio is currently 13.2 days. Approximately 36.4% of the shares of the stock are sold short. View Akcea Therapeutics' Current Options Chain.

Some companies that are related to Akcea Therapeutics include Bausch Health Companies (BHC), Reata Pharmaceuticals (RETA), Amarin (AMRN), Forty Seven (FTSV), United Therapeutics (UTHR), Mirati Therapeutics (MRTX), Evotec (EVTCY), BridgeBio Pharma (BBIO), Global Blood Therapeutics (GBT), Blueprint Medicines (BPMC), Nektar Therapeutics (NKTR), Zai Lab (ZLAB), FibroGen (FGEN), Arrowhead Pharmaceuticals (ARWR) and PTC Therapeutics (PTCT).

Based on aggregate information from My MarketBeat watchlists, some companies that other Akcea Therapeutics investors own include Ionis Pharmaceuticals (IONS), Intelsat (I), Bank of America (BAC), Fossil Group (FOSL), Achaogen (AKAO), Ciena (CIEN), AMC Entertainment (AMC), Apollo Global Management (APO), Associated British Foods (ABF) and Chaarat Gold (CGH).

(AKCA) raised $125 million in an initial public offering on Friday, July 14th 2017. The company issued 9,600,000 shares at a price of $12.00-$14.00 per share. Cowen and Company, Stifel and Wells Fargo Securities acted as the underwriters for the IPO and BMO Capital Markets was co-manager.

Akcea Therapeutics trades on the NASDAQ under the ticker symbol "AKCA."

Akcea Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include FMR LLC (11.50%), State Street Corp (0.71%), Point72 Asset Management L.P. (0.27%), Geode Capital Management LLC (0.27%), Charles Schwab Investment Management Inc. (0.16%) and Russell Investments Group Ltd. (0.12%). Company insiders that own Akcea Therapeutics stock include Damien Mcdevitt, Ionis Pharmaceuticals Inc, Jeff Marc Goldberg, Joshua F Patterson, Kyle Jenne, Paula Soteropoulos and Sarah Boyce. View institutional ownership trends for Akcea Therapeutics.

AKCA stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Rafferty Asset Management LLC, Geode Capital Management LLC, ProShare Advisors LLC, Nuveen Asset Management LLC, and Motley Fool Asset Management LLC. Company insiders that have sold Akcea Therapeutics company stock in the last year include Damien Mcdevitt, Jeff Marc Goldberg, Joshua F Patterson, Kyle Jenne, Paula Soteropoulos, and Sarah Boyce. View insider buying and selling activity for Akcea Therapeutics.

AKCA stock was acquired by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Renaissance Technologies LLC, Russell Investments Group Ltd., State Street Corp, Charles Schwab Investment Management Inc., Amia Capital LLP, Virtus ETF Advisers LLC, and California Public Employees Retirement System. View insider buying and selling activity for Akcea Therapeutics.

Shares of AKCA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of AKCA stock can currently be purchased for approximately $13.31.

Akcea Therapeutics has a market capitalization of $1.35 billion and generates $488.54 million in revenue each year. The company earns $40.77 million in net income (profit) each year or $0.48 on an earnings per share basis. Akcea Therapeutics employs 248 workers across the globe. View additional information about Akcea Therapeutics.

The official website for Akcea Therapeutics is http://www.akceatx.com/.

Akcea Therapeutics' mailing address is 22 BOSTON WHARF RD 9TH FLOOR, BOSTON MA, 02210. The company can be reached via phone at 617-207-0202 or via email at [email protected]